🇺🇸 FDA
Patent

US 11040959

Diprovocims: a new and potent class of TLR agonists

granted A61PA61P37/04

Quick answer

US patent 11040959 (Diprovocims: a new and potent class of TLR agonists) held by The Board of Regents of the University of Texas System expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P37/04